Literature DB >> 28984077

Broad clinical high-risk mental state (CHARMS): Methodology of a cohort study validating criteria for pluripotent risk.

Jessica A Hartmann1,2, Barnaby Nelson1,2, Rachael Spooner1,2, G Paul Amminger1,2, Andrew Chanen1,2, Christopher G Davey1,2, Meredith McHugh1,2, Aswin Ratheesh1,2, Devi Treen3, Hok Pan Yuen1,2, Patrick D McGorry1,2.   

Abstract

AIM: The development of the ultra-high risk (UHR) criteria for psychosis created a new paradigm for the prevention research in psychiatry. Since (1) prevention research faces the challenge of achieving adequate statistical power when focusing on single low-incidence syndromes and (2) early clinical phenotypes are overlapping and non-specific, this study broadens the UHR state beyond psychosis as an outcome. The CHARMS (clinical high at-risk mental state) study aims to prospectively validate a set of trans-diagnostic criteria to identify help-seeking young people at risk of developing a range of serious mental illnesses.
METHODS: This paper describes the methodology of the CHARMS study, which involves applying the CHARMS criteria to a cohort of help-seeking young people aged 12 to 25 attending youth mental health services in Melbourne. New referrals meeting the CHARMS criteria are allocated to the CHARMS+ group; referrals not meeting CHARMS threshold are allocated to CHARMS- group (control group); referrals meeting criteria for a full-threshold disorder are excluded. Transition status and clinical and functional outcomes are re-assessed at 6 and 12 months.
CONCLUSIONS: This study will be the first to introduce and validate clinical criteria to identify a broader at-risk patient population, which may facilitate young people's access to clinical services and early treatment by reducing the reliance on "caseness" defined according to current diagnostic categories being required for service entry. These criteria may introduce a new, trans-diagnostic approach for understanding risk factors and pathogenic mechanisms that drive the onset of severe mental illness and the next generation of preventive intervention trials.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  at-risk mental state; clinical criteria; pluripotential; sub-threshold states; trans-diagnostic

Mesh:

Year:  2017        PMID: 28984077     DOI: 10.1111/eip.12483

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  10 in total

1.  Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry.

Authors:  Patrick D McGorry; Jessica A Hartmann; Rachael Spooner; Barnaby Nelson
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Dual-harm in adolescence and associated clinical and parenting factors.

Authors:  Pascalle Spaan; Philip J S Michielsen; Nita G M de Neve-Enthoven; Diandra C Bouter; Nina H Grootendorst-van Mil; Witte J G Hoogendijk; Sabine J Roza
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-03-29       Impact factor: 4.519

3.  COVID-19 and Youth Psychopathological Distress in Umbria, Central Italy: A 2-Year Observational Study in a Real-World Setting.

Authors:  Giulia Menculini; Giorgio Pomili; Francesca Brufani; Agnese Minuti; Niccolò Mancini; Martina D'Angelo; Sonia Biscontini; Enrico Mancini; Andrea Savini; Laura Orsolini; Umberto Volpe; Alfonso Tortorella; Luca Steardo
Journal:  Front Psychiatry       Date:  2022-05-19       Impact factor: 5.435

4.  Predictors of Outcomes in Adolescents With Clinical High Risk for Psychosis, Other Psychiatric Symptoms, and Psychosis: A Longitudinal Protocol Study.

Authors:  Silvia Molteni; Eleonora Filosi; Maria Martina Mensi; Giulia Spada; Chiara Zandrini; Federica Ferro; Matteo Paoletti; Anna Pichiecchio; Ilaria Bonoldi; Umberto Balottin
Journal:  Front Psychiatry       Date:  2019-12-03       Impact factor: 4.157

5.  Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach.

Authors:  Jessica A Hartmann; Patrick D McGorry; Louise Destree; G Paul Amminger; Andrew M Chanen; Christopher G Davey; Rachid Ghieh; Andrea Polari; Aswin Ratheesh; Hok Pan Yuen; Barnaby Nelson
Journal:  Front Psychiatry       Date:  2021-01-08       Impact factor: 4.157

6.  Editorial: Children, Adolescents and Families With Severe Mental Illness: Toward a Comprehensive Early Identification of Risk.

Authors:  Andrea Raballo; Frauke Schultze-Lutter; Marco Armando
Journal:  Front Psychiatry       Date:  2021-12-21       Impact factor: 4.157

7.  Application of the unified protocol for the transdiagnostic treatment of comorbid emotional disorders in patients with ultra-high risk of developing psychosis: A randomized trial study protocol.

Authors:  Trinidad Peláez; Raquel López-Carrillero; Marta Ferrer-Quintero; Susana Ochoa; Jorge Osma
Journal:  Front Psychol       Date:  2022-09-01

8.  Study Protocol for a Prospective Longitudinal Cohort Study to Identify Proteomic Predictors of Pluripotent Risk for Mental Illness: The Seoul Pluripotent Risk for Mental Illness Study.

Authors:  Tae Young Lee; Junhee Lee; Hyun Ju Lee; Yunna Lee; Sang Jin Rhee; Dong Yeon Park; Myung Jae Paek; Eun Young Kim; Euitae Kim; Sungwon Roh; Hee Yeon Jung; Minah Kim; Se Hyun Kim; Dohyun Han; Yong Min Ahn; Kyooseob Ha; Jun Soo Kwon
Journal:  Front Psychiatry       Date:  2020-04-21       Impact factor: 4.157

9.  Specificity of psychopathology across levels of severity: a transdiagnostic network analysis.

Authors:  Robin N Groen; Marieke Wichers; Johanna T W Wigman; Catharina A Hartman
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

10.  Effects of a Novel, Transdiagnostic, Hybrid Ecological Momentary Intervention for Improving Resilience in Youth (EMIcompass): Protocol for an Exploratory Randomized Controlled Trial.

Authors:  Anita Schick; Isabell Paetzold; Christian Rauschenberg; Dusan Hirjak; Tobias Banaschewski; Andreas Meyer-Lindenberg; Jan R Boehnke; Benjamin Boecking; Ulrich Reininghaus
Journal:  JMIR Res Protoc       Date:  2021-12-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.